Health
Enhancement Products Files for Patent Covering
ProAlgaZyme Product
April 29 2004, 08:30am
ET
TEMPE,
Ariz., April 29/PRNewswire-FirstCall/ -
Health Enhancement Products, Inc. today
announced that it has filed a patent application
with the U.S. Patent and Trademark Office,
relating generally to a method of preparation
of a phyto-percolate. This patent filing
will also protect the use of phyto-percolate
in the treatment of a variety of diseases
including cancer, cardiovascular disease,
and diseases related to immune system deficient
disorders. The phyto-percolate is a proteolytic
enzyme complex derived from a specific combination
of fresh water algae that expresses plasmin-like
activity. As humans' age and chronic disease
processes progress, a deficiency of the
proteolytic enzymes that carry out the body's
waste detoxification processes may be experienced.
A deficiency of this enzyme can cause a
chronic hyper-inflammatory state, and the
disease process becomes much more complex.
Without adequate enzymes in the body, the
immune system and other metabolic processes
become less efficient, making tissue repair
slow and poorly replicated.
The patent application
is for a method of treating or preventing
a disease or disorder in a human by ingesting
a phyto-percolate derived from mixtures
including freshwater algae, in this case
being ProAglaZyme. There are several aspects
of this patent application, including methods
of treating immune system deficiency, type
I and II diabetes, diseases related to the
heart, Cancer, Arthritis, and most other
diseases related to a deficient immune system.
Howard Baer, Chief Executive
Officer of Health Enhancement Products,
Inc., said, "Based on the preliminary
results we have had with our various studies
involving ProAlgaZyme, filing for this patent
was a logical step. We have several different
initiatives underway and want to be able
to legally protect our interests appropriately."
About
Health Enhancement Products, Inc.
Health Enhancement
Products, Inc. (OTC:
HEPI) is a nutraceutical company directed
specifically at the development and marketing
of supplementary health-enhancing products
using only pure, all-natural and herbal
extracts. In particular, Health Enhancement's
products use beneficial herbal extracts,
vitamins, minerals, and botanical extracts
in varying combinations to address common
or specific illnesses.
The Company's sole product is ProAlgaZyme that is produced from an algae grown in 100% distilled water. The algae produces an enzyme as a
means of protecting itself from exposure
to outside disease and harmful bacteria.
The enzyme is then drawn off, filtered,
tested and bottled for consumption. Recent
clinical trials performed by the Company
have indicated that ProAlgaZyme may increase
and activate the white blood cells in individuals
whose white cells are low or inactive, in
effect enhancing the immune system. Heath
Enhancements is currently doing internal
clinical trials on several illnesses and
diseases with ProAlgaZyme, including various
types of cancer, HIV/AIDS, diabetes and
Chronic Fatigue Syndrome.
ReplenTish is currently available for sale
exclusively on
our websites www.heponline.com
or www.replentish.com
.
CONTACTS:
Health Enhancement Products, Inc.
480-385-3800
This press release may contain forward-looking
statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking
statements, which speak only as to the date
the statement was made. The company undertakes
no obligation to publicly update or revise
any forward-looking statements, whether because
of new information, future events, or otherwise.
Forward-looking statements are inherently
subject to risks and uncertainties, some of
which cannot be predicted, or quantified.
Future events and actual results could differ
materially from those set forth in, contemplated
by, or underlying the forward-looking statements.
The risks and uncertainties to which forward-looking
statements are subject include, but are not
limited to, the effect of government regulation,
competition and other material risks.
|